-
Mashup Score: 1
Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55)
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Amer Zeidan, MBBS, MHS, appointed inaugural Chief of the Division of Hematologic Malignancies - 2 month(s) ago
After an extensive national search, Amer Zeidan, MBBS, MHS, has been appointed inaugural Chief of the Division of Hematologic Malignancies at Yale Cancer Center
Source: medicine.yale.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML - The ASCO Post - 2 month(s) ago
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Ninety-one patients from nine sites in France, Italy, Spain, and the United States were enrolled in the first-in-human study between December 2017 and May 2020. The dose-escalation phase examined dose levels of pivekimab sunirine
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10-20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris®) is the only approved treatment for BPDCN; in the United States it is approved for patient …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Team - 2 month(s) ago
Visit the post for more.
Source: www.rumiskitchen.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 180Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera | NEJM - 3 month(s) ago
Original Article from The New England Journal of Medicine — Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Moving toward disease modification in polycythemia vera - 3 month(s) ago
Polycythemia vera is a BCR-ABL1–negative myeloproliferative neoplasm that reduces life expectancy through thrombosis, marrow failure, and transformation to leuk
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 51Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm - 4 month(s) ago
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy1-3 with an overall incidence of approximately 500 to 1000 cases per year in the US and a greater prevalence in those aged 60 years or older. However, the true incidence of BPDCN is likely higher than these numbers indicate, as there may be substantial under-reporting. The median age of patients with BPDCN is 65 to 70 years.4-6 Men are affected at a roughly 3-to-1 ratio to women.1-3,6-9 Pediatric cases represent approximately 10% of total cases and are reportedly less severe, with greater potential for long-lasting remission or cure.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 42A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia - 4 month(s) ago
Key Points. Low-intensity chemotherapy plus venetoclax was safe and active in heavily pretreated relapsed/refractory ALLThe CR/CRi rate of 57% compares favorabl
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
We invite you to join a Post ASH 2023 round table debate dedicated to the hottest MPN findings from ASH 2023 Speakers: Claire Harrison Tania Jain Jean-Jacques Kiladjian Ruben Mesa Naveen Pemmaraju Mohamad Mohty
Source: us06web.zoom.usCategories: General Medicine News, Hem/OncsTweet
Research To Practice | Oncology Videos: Blastic Plasmacytoid Dendritic Cell Neoplasm | Oncology Today with Dr Neil Love and Dr Naveen Pemmaraju @doctorpemm | Blastic Plasmacytoid Dendritic Cell Neoplasm #BPDCN | https://t.co/FIExpko8ZE